Claims for Patent: 8,637,469

Summary for Patent: 8,637,469

Title:	Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
Abstract:	The invention describes a method of treating upper airway disease by administering a composition of one or more proinflammatory cytokine inhibitors sufficient to inhibit inflammation in the upper airways. The proinflammatory cytokines that are inhibited include TNF, IL-1 and IL-8. A medication dispensing unit which includes a container and a delivery system is used to administer the composition. The delivery system further encompasses a one-way valve, a microcatheter, or a liquid-pressure type sprayer.
Inventor(s):	Levitt; Roy Clifford (Coconut Grove, FL)
Assignee:	Levitt; Roy C. (Coconut Grove, FL)
Application Number:	12/373,448
Patent Claims:	1. A method of reducing or ameliorating the progression, severity and/or duration of an inflammatory disease of upper airways in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising one or more IL-1 specific inhibitors, wherein the inflammatory disease of the upper airways is non-allergic in origin. 2. The method of claim 1, wherein the therapeutically effective amount inhibits an inflammation in lower airways of the subject. 3. The method of claim 1, wherein the administration is perioral, intranasal, topical, transdermal, or parenteral. 4. The method of claim 1, wherein the therapeutically effective amount of a composition comprising one or more IL-1 specific inhibitors is from about 0.1 mg to about 100 mg daily administered in single or divided doses. 5. The method of claim 1, wherein said composition is administered as a spray, aerosol, gel, solution, emulsion, or suspension. 6. The method of claim 5, wherein said composition is administered directly to the upper airways. 7. The method of claim 1, wherein said composition is administered directly to paranasal sinuses of the subject. 8. The method of claim 7, wherein said composition is administered via microcatheter. 9. The method of claim 1, wherein the IL-1 specific inhibitors are IL-1 receptor antagonists. 10. The method of claim 1, wherein the IL-1 specific inhibitors are Anakinra. 11. The method of claim 1, wherein the composition consists of the IL-1 specific inhibitors and a carrier. 12. The method of claim 1, wherein the composition consists of an IL-1 receptor antagonist and a carrier. 13. The method of claim 1, wherein the composition consists of Anakinra and a carrier. 14. The method of claim 1, wherein the inflammatory disease of the upper airways is chronic. 15. The method of claim 1, wherein the subject is human. 16. The method of claim 1, wherein the method excludes administering any TNF-.alpha. inhibitor.

Details for Patent 8,637,469

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	11/14/2001		2026-07-11